Multiple sclerosis (MS) is a disease in which genetic, environmental, and stochastic factors interact to trigger an inflammatory disease of the CNS that also has a neurodegenerative component. Over the past 3 years, progress in high-throughput technologies and analysis methods has synergized with the collaborative efforts of investigators studying MS genetics to enable the discovery of more than a dozen genes involved in making individuals susceptible to MS. These genes are beginning to suggest molecular pathways that may be particularly vulnerable to genetic variation in MS. Soon, a comprehensive map of common genetic variants affecting MS susceptibility will be assembled, and communal efforts will need to focus on the more challenging issue of understanding the genetic architecture of disease course and treatment response in MS. Early efforts integrating different dimensions of information, including genomics, imaging, transcriptomics, and proteomics, with precise phenotypic data from clinicians illustrate the way forward for prognostic algorithms in MS and suggest that these approaches will yield a new series of insights in the next decade.
Relationship Disclosure: Dr De Jager has received personal compensation for consulting activities from Merck Serono. Dr De Jager's compensation and/or research work has been funded entirely or in part by a grant to his university froma governmental organization. The grant agreement requires that the nameof the funding entity and the purpose of the grantmay not be disclosed. Dr Esposito's compensation and/or research work has been funded entirely or in part by a grant to her university froma governmental organization. The grant agreement requires that the name of the funding entity and the purpose of the grant may not be disclosed.
Unlabeled Use of Products/Investigational Use Disclosure: Drs De Jager and Esposito have nothing to disclose.